Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute

Kazunori Ida, Satoshi Kawaguchi, Yuriko Sato, Tomohide Tsukahara, Yuki Nabeta, Hiroeki Sahara, Hideyuki Ikeda, Toshihiko Torigoe, Shingo Ichimiya, Kenjiro Kamiguchi, Takuro Wada, Satoshi Nagoya, Hiroaki Hiraga, Akira Kawai, Takeshi Ishii, Nobuhito Araki, Akira Myoui, Seiichi Matsumoto, Toshihumi Ozaki, Hideki YoshikawaToshihiko Yamashita, Noriyuki Sato

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

To investigate the effects of anchor substitutions in SYT-SSX junction peptide, an HLA-A24 anchor residue (position 9) of the SYT-SSX B peptide (GYDQIMPKK) was substituted to more favorable residues according to the HLA-A24-binding motif. Among four substitutes constructed, a substitute with isoleucine (termed K9I peptide) most apparently enhanced the affinity for HLA-A24 molecule. Subsequent in vitro CTL induction analysis using PBMCs of 15 HLA-A24+ synovial sarcoma patients revealed that the original B peptide allowed to induce synovial sarcoma-specific CTLs from 7 patients (47%), whereas such CTLs were inducible from 12 patients (80%) with K9I peptide. Moreover, the extent of cytotoxicity against HLA-A24+ synovial sarcoma cell lines was higher in K9I peptide-induced CTLs than B peptide-induced CTLs. Influence of anchor substitution on peptide/TCR interaction was evaluated by cytotoxicity assays against autologous cells and tetramer analysis. CTLs induced from a synovial sarcoma patient using K9I peptide did not lyse autologous PHA blasts or EBV-infected B cells. In vitro stimulations of PBMCs from 5 HLA-A24+ synovial sarcoma patients with K9I peptide increased the frequency of T cells reacting with both HLA-A24/K9I peptide tetramer and HLA-A24/B peptide tetramer. In contrast, the frequency of T cells reacting with HLA/HIV-derived peptide tetramer remained low. These findings support the validity in design of anchor residue substitution in SYT-SSX fusion gene-derived peptide, and provide a potential clue to the current stagnation in vaccination trials of fusion gene-derived natural junction peptides.

Original languageEnglish
Pages (from-to)1436-1443
Number of pages8
JournalJournal of Immunology
Volume173
Issue number2
Publication statusPublished - Jul 15 2004

Fingerprint

HLA-A Antigens
HLA-A24 Antigen
Peptides
Synovial Sarcoma
Gene Fusion
T-Lymphocytes
HLA-B Antigens
Isoleucine
Human Herpesvirus 4
Vaccination
B-Lymphocytes
HIV

ASJC Scopus subject areas

  • Immunology

Cite this

Ida, K., Kawaguchi, S., Sato, Y., Tsukahara, T., Nabeta, Y., Sahara, H., ... Sato, N. (2004). Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. Journal of Immunology, 173(2), 1436-1443.

Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. / Ida, Kazunori; Kawaguchi, Satoshi; Sato, Yuriko; Tsukahara, Tomohide; Nabeta, Yuki; Sahara, Hiroeki; Ikeda, Hideyuki; Torigoe, Toshihiko; Ichimiya, Shingo; Kamiguchi, Kenjiro; Wada, Takuro; Nagoya, Satoshi; Hiraga, Hiroaki; Kawai, Akira; Ishii, Takeshi; Araki, Nobuhito; Myoui, Akira; Matsumoto, Seiichi; Ozaki, Toshihumi; Yoshikawa, Hideki; Yamashita, Toshihiko; Sato, Noriyuki.

In: Journal of Immunology, Vol. 173, No. 2, 15.07.2004, p. 1436-1443.

Research output: Contribution to journalArticle

Ida, K, Kawaguchi, S, Sato, Y, Tsukahara, T, Nabeta, Y, Sahara, H, Ikeda, H, Torigoe, T, Ichimiya, S, Kamiguchi, K, Wada, T, Nagoya, S, Hiraga, H, Kawai, A, Ishii, T, Araki, N, Myoui, A, Matsumoto, S, Ozaki, T, Yoshikawa, H, Yamashita, T & Sato, N 2004, 'Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute', Journal of Immunology, vol. 173, no. 2, pp. 1436-1443.
Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. Journal of Immunology. 2004 Jul 15;173(2):1436-1443.
Ida, Kazunori ; Kawaguchi, Satoshi ; Sato, Yuriko ; Tsukahara, Tomohide ; Nabeta, Yuki ; Sahara, Hiroeki ; Ikeda, Hideyuki ; Torigoe, Toshihiko ; Ichimiya, Shingo ; Kamiguchi, Kenjiro ; Wada, Takuro ; Nagoya, Satoshi ; Hiraga, Hiroaki ; Kawai, Akira ; Ishii, Takeshi ; Araki, Nobuhito ; Myoui, Akira ; Matsumoto, Seiichi ; Ozaki, Toshihumi ; Yoshikawa, Hideki ; Yamashita, Toshihiko ; Sato, Noriyuki. / Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. In: Journal of Immunology. 2004 ; Vol. 173, No. 2. pp. 1436-1443.
@article{e6f973b900bd44aaa97648659870fa62,
title = "Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute",
abstract = "To investigate the effects of anchor substitutions in SYT-SSX junction peptide, an HLA-A24 anchor residue (position 9) of the SYT-SSX B peptide (GYDQIMPKK) was substituted to more favorable residues according to the HLA-A24-binding motif. Among four substitutes constructed, a substitute with isoleucine (termed K9I peptide) most apparently enhanced the affinity for HLA-A24 molecule. Subsequent in vitro CTL induction analysis using PBMCs of 15 HLA-A24+ synovial sarcoma patients revealed that the original B peptide allowed to induce synovial sarcoma-specific CTLs from 7 patients (47{\%}), whereas such CTLs were inducible from 12 patients (80{\%}) with K9I peptide. Moreover, the extent of cytotoxicity against HLA-A24+ synovial sarcoma cell lines was higher in K9I peptide-induced CTLs than B peptide-induced CTLs. Influence of anchor substitution on peptide/TCR interaction was evaluated by cytotoxicity assays against autologous cells and tetramer analysis. CTLs induced from a synovial sarcoma patient using K9I peptide did not lyse autologous PHA blasts or EBV-infected B cells. In vitro stimulations of PBMCs from 5 HLA-A24+ synovial sarcoma patients with K9I peptide increased the frequency of T cells reacting with both HLA-A24/K9I peptide tetramer and HLA-A24/B peptide tetramer. In contrast, the frequency of T cells reacting with HLA/HIV-derived peptide tetramer remained low. These findings support the validity in design of anchor residue substitution in SYT-SSX fusion gene-derived peptide, and provide a potential clue to the current stagnation in vaccination trials of fusion gene-derived natural junction peptides.",
author = "Kazunori Ida and Satoshi Kawaguchi and Yuriko Sato and Tomohide Tsukahara and Yuki Nabeta and Hiroeki Sahara and Hideyuki Ikeda and Toshihiko Torigoe and Shingo Ichimiya and Kenjiro Kamiguchi and Takuro Wada and Satoshi Nagoya and Hiroaki Hiraga and Akira Kawai and Takeshi Ishii and Nobuhito Araki and Akira Myoui and Seiichi Matsumoto and Toshihumi Ozaki and Hideki Yoshikawa and Toshihiko Yamashita and Noriyuki Sato",
year = "2004",
month = "7",
day = "15",
language = "English",
volume = "173",
pages = "1436--1443",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute

AU - Ida, Kazunori

AU - Kawaguchi, Satoshi

AU - Sato, Yuriko

AU - Tsukahara, Tomohide

AU - Nabeta, Yuki

AU - Sahara, Hiroeki

AU - Ikeda, Hideyuki

AU - Torigoe, Toshihiko

AU - Ichimiya, Shingo

AU - Kamiguchi, Kenjiro

AU - Wada, Takuro

AU - Nagoya, Satoshi

AU - Hiraga, Hiroaki

AU - Kawai, Akira

AU - Ishii, Takeshi

AU - Araki, Nobuhito

AU - Myoui, Akira

AU - Matsumoto, Seiichi

AU - Ozaki, Toshihumi

AU - Yoshikawa, Hideki

AU - Yamashita, Toshihiko

AU - Sato, Noriyuki

PY - 2004/7/15

Y1 - 2004/7/15

N2 - To investigate the effects of anchor substitutions in SYT-SSX junction peptide, an HLA-A24 anchor residue (position 9) of the SYT-SSX B peptide (GYDQIMPKK) was substituted to more favorable residues according to the HLA-A24-binding motif. Among four substitutes constructed, a substitute with isoleucine (termed K9I peptide) most apparently enhanced the affinity for HLA-A24 molecule. Subsequent in vitro CTL induction analysis using PBMCs of 15 HLA-A24+ synovial sarcoma patients revealed that the original B peptide allowed to induce synovial sarcoma-specific CTLs from 7 patients (47%), whereas such CTLs were inducible from 12 patients (80%) with K9I peptide. Moreover, the extent of cytotoxicity against HLA-A24+ synovial sarcoma cell lines was higher in K9I peptide-induced CTLs than B peptide-induced CTLs. Influence of anchor substitution on peptide/TCR interaction was evaluated by cytotoxicity assays against autologous cells and tetramer analysis. CTLs induced from a synovial sarcoma patient using K9I peptide did not lyse autologous PHA blasts or EBV-infected B cells. In vitro stimulations of PBMCs from 5 HLA-A24+ synovial sarcoma patients with K9I peptide increased the frequency of T cells reacting with both HLA-A24/K9I peptide tetramer and HLA-A24/B peptide tetramer. In contrast, the frequency of T cells reacting with HLA/HIV-derived peptide tetramer remained low. These findings support the validity in design of anchor residue substitution in SYT-SSX fusion gene-derived peptide, and provide a potential clue to the current stagnation in vaccination trials of fusion gene-derived natural junction peptides.

AB - To investigate the effects of anchor substitutions in SYT-SSX junction peptide, an HLA-A24 anchor residue (position 9) of the SYT-SSX B peptide (GYDQIMPKK) was substituted to more favorable residues according to the HLA-A24-binding motif. Among four substitutes constructed, a substitute with isoleucine (termed K9I peptide) most apparently enhanced the affinity for HLA-A24 molecule. Subsequent in vitro CTL induction analysis using PBMCs of 15 HLA-A24+ synovial sarcoma patients revealed that the original B peptide allowed to induce synovial sarcoma-specific CTLs from 7 patients (47%), whereas such CTLs were inducible from 12 patients (80%) with K9I peptide. Moreover, the extent of cytotoxicity against HLA-A24+ synovial sarcoma cell lines was higher in K9I peptide-induced CTLs than B peptide-induced CTLs. Influence of anchor substitution on peptide/TCR interaction was evaluated by cytotoxicity assays against autologous cells and tetramer analysis. CTLs induced from a synovial sarcoma patient using K9I peptide did not lyse autologous PHA blasts or EBV-infected B cells. In vitro stimulations of PBMCs from 5 HLA-A24+ synovial sarcoma patients with K9I peptide increased the frequency of T cells reacting with both HLA-A24/K9I peptide tetramer and HLA-A24/B peptide tetramer. In contrast, the frequency of T cells reacting with HLA/HIV-derived peptide tetramer remained low. These findings support the validity in design of anchor residue substitution in SYT-SSX fusion gene-derived peptide, and provide a potential clue to the current stagnation in vaccination trials of fusion gene-derived natural junction peptides.

UR - http://www.scopus.com/inward/record.url?scp=3142700682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142700682&partnerID=8YFLogxK

M3 - Article

C2 - 15240740

AN - SCOPUS:3142700682

VL - 173

SP - 1436

EP - 1443

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -